Rite Aid Agrees To Opioid Settlement

The pharmacy chain Rite Aid has settled a case over its involvement in the state’s opioid crisis.

West Virginia Attorney General Patrick Morrisey announced a settlement Thursday with the pharmacy chain Rite Aid that could provide up to $30 million dollars for recovery efforts in the state. The lawsuit alleged that Rite Aid contributed to the state’s opioid crisis by oversupplying addictive pills.

The West Virginia First Memorandum of Understanding, or MOU, is an agreement by counties and cities on how to spend funds received from opioid settlements. Following the MOU, the settlement funds from Rite Aid go to state and local programs for the reduction of opioid addiction.

In May, Teva and Allergan settled for $161.5 million; in April, drug manufacturers Johnson & Johnson settled for $99 million; and in March, Endo Health Solutions settled for $26 million.

In a July ruling, the three big drug distributors McKesson, Cardinal Health, and AmerisourceBergen were found not liable in a case brought by Cabell County and the City of Huntington. In August, the same distributors settled for $400 million with other cities and counties in the state.

Although Rite Aid settled their case, a trial is set in September as part of the Mass Litigation Panel for remaining pharmacy defendants.

State Officials Announce $4.9 Million Settlement with Rite Aid

West Virginia officials have reached a $4.9 million settlement with Rite Aid in a dispute involving cost savings stemming from generic prescription drugs…

West Virginia officials have reached a $4.9 million settlement with Rite Aid in a dispute involving cost savings stemming from generic prescription drugs sales.

Attorney General Patrick Morrisey made the announcement Tuesday in a news release.

The lawsuit stated that Rite Aid failed to accurately calculate and pass along retail savings from its prescription drugs sale. The lawsuit also said that each instance was a violation of the state’s Consumer Credit and Protection Act.

Rite Aid denies any wrongdoing.

Morrisey says companies choosing to operate in West Virginia must respect its laws.

In addition to paying $4.9 million, the company must implement a compliance program in accordance with the state’s Pharmacy Act, which requires pharmacies to pass retail savings from generic prescription drug sales onto consumers.

Exit mobile version